Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of oxicam NSAIDs

被引：0
|
作者：
Suarez-Kurtz, Guilherme [1 ]
机构：
[1] Inst Nacl Canc, Div Pharmacol, BR-20231050 Rio De Janeiro, Brazil
来源：
PHARMACOGENETICS AND GENOMICS | 2014年 / 24卷 / 08期
关键词：
INDIVIDUALS; EXPOSURE;
D O I：
10.1097/FPC.0000000000000064
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：406 / 407
页数：2
相关论文
共 50 条
  • [41] Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5′-hydroxylation
    Iida, I
    Miyata, A
    Arai, M
    Hirota, M
    Akimoto, M
    Higuchi, S
    Kobayashi, K
    Chiba, K
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (01) : 7 - 9
  • [42] CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects
    Yin, OQP
    Tomlinson, B
    Chow, MSS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (04) : 370 - 377
  • [43] EFFECT OF CYP2C9 GENOTYPE FOR PHARMACOKINETICS OF EFAVIRENZ IN VIVO IN CYNOMOLGUS MONKEYS
    Iwasaki, Kazuhide
    Kitsugi, Yusuke
    Ikeda, Kanami
    Yoshikawa, Takahiro
    Uehara, Shotaro
    Uno, Yasuhiro
    Utoh, Masahiro
    Yamazaki, Hiroshi
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S39 - S39
  • [44] The CYP2C9 genotype does not influence sildenafil pharmacokinetics in healthy volunteers
    Jetter, A
    Lazar, A
    Schömig, E
    Fuhr, U
    Kinzig-Schippers, M
    Sörgel, F
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (04) : 441 - 443
  • [45] Warfarin resistance with poor CYP2C9 activity and CYP2C9*1*2 genotype
    Dericioglu, N
    Babaoglu, MO
    Saygi, S
    Bozkurt, A
    Yasar, U
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (05) : 899 - 899
  • [46] Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects
    Bae, Jung-Woo
    Kim, Ji-Hong
    Choi, Chang-Ik
    Kim, Mi-Jeong
    Kim, Hyung-Ji
    Byun, Seong-Ae
    Chang, Young-Soon
    Jang, Choon-Gon
    Park, Young-Seo
    Lee, Seok-Yong
    ARCHIVES OF PHARMACAL RESEARCH, 2009, 32 (02) : 269 - 273
  • [47] Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria
    Goto, Toshiharu
    Miura, Masatomo
    Murata, Atsunobu
    Terata, Ken
    Uno, Tsukasa
    Yamamoto, Koujirou
    Abe, Yoshihisa
    CLINICA CHIMICA ACTA, 2010, 411 (17-18) : 1375 - 1377
  • [48] Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects
    Jung-Woo Bae
    Ji-Hong Kim
    Chang-Ik Choi
    Mi-Jeong Kim
    Hyung-Ji Kim
    Seong-Ae Byun
    Young-Soon Chang
    Choon-Gon Jang
    Young-Seo Park
    Seok-Yong Lee
    Archives of Pharmacal Research, 2009, 32 : 269 - 273
  • [49] Application of Vivid™ fluorogenic substrates for the in vitro assessment of CYP2C9*1, CYP2C9*2 and CYP2C9*3 metabolism
    Thompson, DV
    Marks, BD
    Goossens, TA
    Trubetskoy, OV
    DRUG METABOLISM REVIEWS, 2002, 34 : 153 - 153
  • [50] Analysis of CYP2C9 promotor variations and possible links to the CYP2C9*2 and CYP2C9*3 exon variants.
    Schubert, C
    Cubic, I
    Kirchheiner, J
    Brockmöller, J
    Roots, I
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (07) : S98 - S98
12345